Research Topics
| L M DemberSummaryAffiliation: Boston University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Case records of the Massachusetts General Hospital. Case 15-2005. An 80-year-old man with shortness of breath, edema, and proteinuriaLaura M Dember
Renal Section, Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, USA
N Engl J Med 352:2111-9. 2005- Light chains, casts, sheets and fibrils: monoclonal immunoglobulin diseases and immunotactoid/fibrillary glomerulopathyLaura M Dember
Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Clin J Am Soc Nephrol 1:1320-1. 2006 - Eprodisate for the treatment of renal disease in AA amyloidosisLaura M Dember
Boston University School of Medicine, Boston, MA 02118, USA
N Engl J Med 356:2349-60. 2007.... - Dialysis-related amyloidosis: late finding or hidden epidemic?Laura M Dember
Renal Section, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Semin Dial 19:105-9. 2006.... - Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis TrialLaura M Dember
Renal Section, Boston University School of Medicine, MA 02118 USA
Clin Trials 2:413-22. 2005..The autogenous arteriovenous fistula created by direct connection of native artery to vein is the recommended vascular access for hemodialysis. However, it fails frequently due to clotting after surgery... 
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trialLaura M Dember
Boston University, School of Medicine, Renal Section, EBRC 504, 650 Albany St, Boston, Massachusetts 02118, USA
JAMA 299:2164-71. 2008..Small, inconclusive trials have suggested that antiplatelet agents may reduce thrombosis of new fistulas...- Critical care issues in the patient with chronic renal failureLaura M Dember
Boston University School of Medicine, Renal Section, Evans Biomedical Research Center, 5th Floor, 650 Albany Street, Boston, MA 02465, USA
Crit Care Clin 18:421-40. 2002..The recognition of ESRD as a state of chronic inflammation and increased oxidative stress ultimately should lead to more effective treatment approaches for several of the comorbid conditions common in this patient population... - Value of static venous pressure for predicting arteriovenous graft thrombosisLaura M Dember
Renal Sections, Boston University School of Medicine and VA Boston Healthcare System, Boston, Massachusetts, USA
Kidney Int 61:1899-904. 2002..However, it is not known how well static venous pressure elevation predicts subsequent AV graft thrombosis... - Modern treatment of amyloidosis: unresolved questionsLaura M Dember
Renal Section, Boston University School of Medicine, Boston, MA 02118, USA
J Am Soc Nephrol 20:469-72. 2009..Additionally, observations from a clinical trial in AA amyloidosis have generated hypotheses about the relative contributions of amyloid precursors and mature fibrils to amyloidosis-associated kidney disease... - Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal diseaseL M Dember
Renal Section, EBRC 504, Boston University Medical Center, 650 Albany Street, Boston, MA 02118, USA
Ann Intern Med 134:746-53. 2001..The impact of this treatment on associated renal disease is not known... - Amyloidosis-associated kidney diseaseLaura M Dember
Renal Section, Boston University School of Medicine, EBRC 504, 650 Albany Street, Boston, MA 02118, USA
J Am Soc Nephrol 17:3458-71. 2006..This article reviews the pathogenesis, diagnosis, clinical manifestations, and treatment of the amyloidoses, focusing heavily on the renal aspects of each of these areas... - An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosisV Sanchorawala
Stem Cell Transplant Program of the Section of Hematology and Oncology, Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
Bone Marrow Transplant 28:637-42. 2001.... - Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosisR L Comenzo
Department of Medicine, Stem Cell Transplant Program, Boston Medical Center and Boston University School of Medicine, Massachusetts 02118, USA
Br J Haematol 104:553-9. 1999..The 100 d mortality was 20%. In conclusion, no definitive differences were identified between the mobilization regimens and IDM was an active regimen in AL for selected patients... - High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trialV Sanchorawala
Hematology and Stem Cell Transplant Programs, Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
Bone Marrow Transplant 33:381-8. 2004.... - Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantationK Weichman
Section of Hematology/Oncology, Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
Bone Marrow Transplant 38:339-43. 2006..In our experience, HDM/SCT is a feasible and effective treatment approach for these disorders... - High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal diseaseLiam F Casserly
Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Kidney Int 63:1051-7. 2003..This treatment should be considered for patients with AL amyloidosis-associated ESRD... - Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosisLaura M Dember
Renal Sections of Boston University School of Medicine, Boston, Massachusetts, USA
Kidney Int 66:390-8. 2004..The present study is a randomized trial comparing prophylactic repair of AV graft stenosis with repair at the time of thrombosis... - Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosisDavid C Seldin
Boston University Medical Center, Boston Medical Center, MA, USA
Clin Lymphoma 3:241-6. 2003..No complete hematologic responses were seen, but 25% of patients had a significant reduction in Bence-Jones proteinuria. Thus, while thalidomide has activity in AL amyloidosis, it also has significant toxicity in this patient population... - Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantationDavid C Seldin
Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
Blood 104:1888-93. 2004..Thus, treatment of AL amyloidosis patients with HDM/SCT produces measurable and sustained improvements in quality of life, particularly in those patients who achieve hematologic CR... - High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year studyMartha Skinner
Boston University School of Medicine, Boston, Massachusetts 02118, USA
Ann Intern Med 140:85-93. 2004..AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective... - Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosisJohn L Berk
Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
Chest 124:969-77. 2003..We hypothesized that disruption of pleural function by amyloid deposits underlies persistent pleural effusions (PPEs) in patients with AL disease... - Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosisVaishali Sanchorawala
Department of Medicine, Section of Hematology Oncology, Boston Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
Br J Haematol 117:886-9. 2002..This regimen appeared to be effective in inducing haematological responses in patients who received total doses of melphalan > 300 mg... - Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosisAmit Fadia
The Renal Section, Stem Cell Transplant Program of the Hematology/Oncology Section, and Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
Kidney Int 63:1868-73. 2003..9 years. CONCLUSION: ARF is a frequent but often reversible complication of HDM/SCT for AL amyloidosis. Specific clinical and treatment-related factors are associated with the development of this complication... - Thrombosis in end-stage renal diseaseLiam F Casserly
Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Semin Dial 16:245-56. 2003..In this article we review the pathogenesis and clinical manifestations of thrombosis in ESRD and evaluate the evidence that chronic renal failure or its management predisposes to thrombotic events... - MRI isolation of infected renal cyst in autosomal dominant polycystic kidney diseaseC Chicoskie
Department of Radiology, Boston Medical Center, 88 East Newton Street, Boston, MA 02118, USA
Clin Imaging 25:114-7. 2001..We suggest that gadolinium-enhanced MR be considered useful in the evaluation of ADPKD patients with suspected infected cyst... 
Kidney dysfunction during lenalidomide treatment for AL amyloidosisRichard Specter
Renal Section, Boston University School of Medicine, Boston, MA, USA
Nephrol Dial Transplant 26:881-6. 2011..The objective of this study is to characterize alterations in kidney function among patients with AL amyloidosis undergoing treatment with lenalidomide...- Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosisHarun Akar
Amyloid Treatment and Research Program at Boston Medical Center, Boston University School of Medicine, Boston, MA, 02118, USA
Amyloid 12:210-5. 2005..After a histologic tissue diagnosis of amyloidosis, determining the type as AL amyloidosis relies on a panel of hematologic tests to determine light chain clonality and the exclusion other forms of amyloidosis... - Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis TrialBradley S Dixon
Nephrology Division, Veterans Affairs Medical Center and University of Iowa School of Medicine, Iowa City 52242 1081, USA
Clin Trials 2:400-12. 2005..The Dialysis Access Consortium (DAC) Aggrenox Prevention of Access Stenosis Trial tests the hypothesis that Aggrenox (containing dipyridamole and aspirin) can prevent stenosis and prolong survival of arteriovenous grafts... - Early fistula failure: back to basicsLaura M Dember
Am J Kidney Dis 50:696-9. 2007 - Emerging treatment approaches for the systemic amyloidosesLaura M Dember
Kidney Int 68:1377-90. 2005
Research Grants
- Dialysis Access Consortium Clinical TrialsLAURA DEMBER; Fiscal Year: 2006....